# Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

> **NCT06422767** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 46 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Bepirovirsen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06422767
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-18
- **Primary completion:** 2025-04-28
- **Final completion:** 2025-04-28
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06422767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06422767, "Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06422767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*